Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1999 Feb;52(2):83–88. doi: 10.1136/jcp.52.2.83

Gynaecological effects of tamoxifen.

S M Ismail 1
PMCID: PMC501045  PMID: 10396232

Full text

PDF
83

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barakat R. R., Wong G., Curtin J. P., Vlamis V., Hoskins W. J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994 Nov;55(2):164–168. doi: 10.1006/gyno.1994.1271. [DOI] [PubMed] [Google Scholar]
  2. Beer T. W., Buchanan R., Buckley C. H. Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol. 1995 Jun;48(6):596–596. doi: 10.1136/jcp.48.6.596-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boccardo F., Bruzzi P., Rubagotti A., Nicolò G. U., Rosso R. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology. 1981;38(5):281–285. doi: 10.1159/000225571. [DOI] [PubMed] [Google Scholar]
  4. Buckley C. H. Tamoxifen and endometriosis. Case report. Br J Obstet Gynaecol. 1990 Jul;97(7):645–646. doi: 10.1111/j.1471-0528.1990.tb02557.x. [DOI] [PubMed] [Google Scholar]
  5. Butta A., MacLennan K., Flanders K. C., Sacks N. P., Smith I., McKinna A., Dowsett M., Wakefield L. M., Sporn M. B., Baum M. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992 Aug 1;52(15):4261–4264. [PubMed] [Google Scholar]
  6. Cabot M. C., Zhang Z. C., Giuliano A. E. Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells. Breast Cancer Res Treat. 1995;36(3):299–306. doi: 10.1007/BF00713401. [DOI] [PubMed] [Google Scholar]
  7. Cabot M. C., Zhang Z., Cao H., Lavie Y., Giuliano A. E., Han T. Y., Jones R. C. Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Int J Cancer. 1997 Mar 4;70(5):567–574. doi: 10.1002/(sici)1097-0215(19970304)70:5<567::aid-ijc13>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  8. Carmichael P. L., Ugwumadu A. H., Neven P., Hewer A. J., Poon G. K., Phillips D. H. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 1996 Apr 1;56(7):1475–1479. [PubMed] [Google Scholar]
  9. Charlier C., Bruyneel E., Lechanteur C., Bracke M., Mareel M., Castronovo V. Enhancement of tamoxifen-induced E-cadherin function by Ca2+ channel antagonists in human breast cancer MCF7/6 cells. Eur J Pharmacol. 1996 Dec 19;317(2-3):413–416. doi: 10.1016/s0014-2999(96)00816-3. [DOI] [PubMed] [Google Scholar]
  10. Chau D., Mancoll J. S., Lee S., Zhao J., Phillips L. G., Gittes G. K., Longaker M. T. Tamoxifen downregulates TGF-beta production in keloid fibroblasts. Ann Plast Surg. 1998 May;40(5):490–493. doi: 10.1097/00000637-199805000-00008. [DOI] [PubMed] [Google Scholar]
  11. Cheng W. F., Lin H. H., Torng P. L., Huang S. C. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997 Aug;66(2):233–237. doi: 10.1006/gyno.1997.4739. [DOI] [PubMed] [Google Scholar]
  12. Chez R. A. Woman battering. Am J Obstet Gynecol. 1988 Jan;158(1):1–4. doi: 10.1016/0002-9378(88)90764-8. [DOI] [PubMed] [Google Scholar]
  13. Clement P. B., Oliva E., Young R. H. Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions. Int J Gynecol Pathol. 1996 Jul;15(3):222–229. doi: 10.1097/00004347-199607000-00006. [DOI] [PubMed] [Google Scholar]
  14. Clement P. B., Scully R. E. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990 Apr;21(4):363–381. doi: 10.1016/0046-8177(90)90198-e. [DOI] [PubMed] [Google Scholar]
  15. Cohen I., Altaras M. M., Lew S., Tepper R., Beyth Y., Ben-Baruch G. Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy: a case report and review of the literature. Gynecol Oncol. 1994 Dec;55(3 Pt 1):443–447. doi: 10.1006/gyno.1994.1319. [DOI] [PubMed] [Google Scholar]
  16. Cohen I., Beyth Y., Tepper R., Figer A., Shapira J., Cordoba M., Yigael D., Altaras M. M. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol. 1995 Jul;58(1):86–91. doi: 10.1006/gyno.1995.1188. [DOI] [PubMed] [Google Scholar]
  17. Cohen I., Beyth Y., Tepper R., Shapira J., Zalel Y., Figer A., Cordoba M., Yigael D., Altaras M. M. Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol. 1996 Jan;60(1):54–58. doi: 10.1006/gyno.1996.0011. [DOI] [PubMed] [Google Scholar]
  18. Cohen I., Rosen D. J., Altaras M., Beyth Y., Shapira J., Yigael D. Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth. Br J Cancer. 1994 Mar;69(3):620–621. doi: 10.1038/bjc.1994.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cohen I., Rosen D. J., Shapira J., Cordoba M., Gilboa S., Altaras M. M., Yigael D., Beyth Y. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol. 1993 Jun;100(6):567–570. doi: 10.1111/j.1471-0528.1993.tb15310.x. [DOI] [PubMed] [Google Scholar]
  20. Cohen I., Rosen D. J., Shapira J., Cordoba M., Gilboa S., Altaras M. M., Yigael D., Beyth Y. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol. 1994 Feb;52(2):185–190. doi: 10.1006/gyno.1994.1029. [DOI] [PubMed] [Google Scholar]
  21. Corley D., Rowe J., Curtis M. T., Hogan W. M., Noumoff J. S., Livolsi V. A. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 1992 Jan;79(1):111–116. [PubMed] [Google Scholar]
  22. Dragan Y. P., Xu Y. D., Pitot H. C. Tumor promotion as a target for estrogen/antiestrogen effects in rat hepatocarcinogenesis. Prev Med. 1991 Jan;20(1):15–26. doi: 10.1016/0091-7435(91)90003-m. [DOI] [PubMed] [Google Scholar]
  23. Duh J. L., Yu R., Jiao J. J., Matwyshyn G. A., Li W., Tan T. H., Kong A. N. Activation of signal transduction kinases by tamoxifen. Pharm Res. 1997 Feb;14(2):186–189. doi: 10.1023/a:1012048626963. [DOI] [PubMed] [Google Scholar]
  24. Eddy G. L., Mazur M. T. Endolymphatic stromal myosis associated with tamoxifen use. Gynecol Oncol. 1997 Feb;64(2):262–264. doi: 10.1006/gyno.1996.4552. [DOI] [PubMed] [Google Scholar]
  25. Eells T. P., Alpern H. D., Grzywacz C., MacMillan R. W., Olson J. E. The effect of tamoxifen on cervical squamous maturation in Papanicolaou stained cervical smears of post-menopausal women. Cytopathology. 1990;1(5):263–268. doi: 10.1111/j.1365-2303.1990.tb00359.x. [DOI] [PubMed] [Google Scholar]
  26. Elkas J., Gray K., Howard L., Petit N., Pohl J., Armstrong A. The effects of tamoxifen on endometrial insulin-like growth factor-1 expression. Obstet Gynecol. 1998 Jan;91(1):45–50. doi: 10.1016/s0029-7844(97)00549-8. [DOI] [PubMed] [Google Scholar]
  27. Evans M.J., Langlois N.E.I., Kitchener H.C., Miller I.D. Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus? Int J Gynecol Cancer. 1995 Jul;5(4):310–313. doi: 10.1046/j.1525-1438.1995.05040310.x. [DOI] [PubMed] [Google Scholar]
  28. Ferrazzi E., Cartei G., Mattarazzo R., Fiorentino M. Oestrogen-like effect of tamoxifen on vaginal epithelium. Br Med J. 1977 May 21;1(6072):1351–1352. doi: 10.1136/bmj.1.6072.1351-e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Fisher B., Costantino J. P., Redmond C. K., Fisher E. R., Wickerham D. L., Cronin W. M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994 Apr 6;86(7):527–537. doi: 10.1093/jnci/86.7.527. [DOI] [PubMed] [Google Scholar]
  30. Fisher B., Costantino J., Redmond C., Poisson R., Bowman D., Couture J., Dimitrov N. V., Wolmark N., Wickerham D. L., Fisher E. R. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484. doi: 10.1056/NEJM198902233200802. [DOI] [PubMed] [Google Scholar]
  31. Fornander T., Rutqvist L. E., Cedermark B., Glas U., Mattsson A., Silfverswärd C., Skoog L., Somell A., Theve T., Wilking N. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989 Jan 21;1(8630):117–120. doi: 10.1016/s0140-6736(89)91141-0. [DOI] [PubMed] [Google Scholar]
  32. Ghia M., Mereto E. Induction and promotion of gamma-glutamyltranspeptidase-positive foci in the liver of female rats treated with ethinyl estradiol, clomiphene, tamoxifen and their associations. Cancer Lett. 1989 Aug;46(3):195–202. doi: 10.1016/0304-3835(89)90130-4. [DOI] [PubMed] [Google Scholar]
  33. Goldstein S. R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1994 Feb;170(2):447–451. doi: 10.1016/s0002-9378(94)70209-8. [DOI] [PubMed] [Google Scholar]
  34. Groom G. V., Griffiths K. Effect of the anti-oestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal pre-menopausal women. J Endocrinol. 1976 Sep;70(3):421–428. doi: 10.1677/joe.0.0700421. [DOI] [PubMed] [Google Scholar]
  35. Gundimeda U., Chen Z. H., Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem. 1996 Jun 7;271(23):13504–13514. doi: 10.1074/jbc.271.23.13504. [DOI] [PubMed] [Google Scholar]
  36. Hajjar L. R., Kim W., Nolan G. H., Turner S., Raju U. R. Intestinal and pelvic endometriosis presenting as a tumor and associated with tamoxifen therapy: report of a case. Obstet Gynecol. 1993 Oct;82(4 Pt 2 Suppl):642–644. [PubMed] [Google Scholar]
  37. Han X. L., Liehr J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 1992 Mar 1;52(5):1360–1363. [PubMed] [Google Scholar]
  38. Hemminki K., Rajaniemi H., Lindahl B., Moberger B. Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 1996 Oct 1;56(19):4374–4377. [PubMed] [Google Scholar]
  39. Hochner-Celnikier D., Anteby E., Yagel S. Ovarian cysts in tamoxifen-treated premenopausal women with breast cancer--a management dilemma. Am J Obstet Gynecol. 1995 Apr;172(4 Pt 1):1323–1324. doi: 10.1016/0002-9378(95)91511-7. [DOI] [PubMed] [Google Scholar]
  40. Huynh H. T., Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res. 1993 Dec 1;53(23):5585–5588. [PubMed] [Google Scholar]
  41. Huynh H. T., Tetenes E., Wallace L., Pollak M. In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Res. 1993 Apr 15;53(8):1727–1730. [PubMed] [Google Scholar]
  42. Huynh H., Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res. 1994 Jun 15;54(12):3115–3119. [PubMed] [Google Scholar]
  43. Hyder S. M., Stancel G. M., Chiappetta C., Murthy L., Boettger-Tong H. L., Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res. 1996 Sep 1;56(17):3954–3960. [PubMed] [Google Scholar]
  44. Ismail S. M., Maulik T. G. Tamoxifen-associated post-menopausal endometriosis. Histopathology. 1997 Feb;30(2):187–191. doi: 10.1046/j.1365-2559.1997.d01-576.x. [DOI] [PubMed] [Google Scholar]
  45. Ismail S. M. Pathology of endometrium treated with tamoxifen. J Clin Pathol. 1994 Sep;47(9):827–833. doi: 10.1136/jcp.47.9.827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Jordan V. C., Fritz N. F., Langan-Fahey S., Thompson M., Tormey D. C. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst. 1991 Oct 16;83(20):1488–1491. doi: 10.1093/jnci/83.20.1488. [DOI] [PubMed] [Google Scholar]
  47. Jordan V. C., Fritz N. F., Tormey D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res. 1987 Jan 15;47(2):624–630. [PubMed] [Google Scholar]
  48. Josefson D. Breast cancer trial stopped early. BMJ. 1998 Apr 18;316(7139):1187–1187. doi: 10.1136/bmj.316.7139.1185d. [DOI] [PubMed] [Google Scholar]
  49. Kang Y., Cortina R., Perry R. R. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. J Natl Cancer Inst. 1996 Mar 6;88(5):279–284. doi: 10.1093/jnci/88.5.279. [DOI] [PubMed] [Google Scholar]
  50. Kedar R. P., Bourne T. H., Powles T. J., Collins W. P., Ashley S. E., Cosgrove D. O., Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318–1321. doi: 10.1016/s0140-6736(94)92466-x. [DOI] [PubMed] [Google Scholar]
  51. Laatikainen T. J., Tomás E. I., Voutilainen R. J. The expression of insulin-like growth factor and its binding protein mRNA in the endometrium of postmenopausal patients with breast cancer receiving tamoxifen. Cancer. 1995 Oct 15;76(8):1406–1410. doi: 10.1002/1097-0142(19951015)76:8<1406::aid-cncr2820760816>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  52. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P. J., Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993 May;81(5 ):660–664. [PubMed] [Google Scholar]
  53. Lahti E., Vuopala S., Kauppila A., Blanco G., Ruokonen A., Laatikainen T. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen. Gynecol Oncol. 1994 Dec;55(3 Pt 1):410–414. doi: 10.1006/gyno.1994.1314. [DOI] [PubMed] [Google Scholar]
  54. Li D., Dragan Y., Jordan V. C., Wang M., Pitot H. C. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 1997 Apr 15;57(8):1438–1441. [PubMed] [Google Scholar]
  55. Lindahl B., Andolf E., Ingvar C., Liedman R., Ranstam J., Willén R. Endometrial thickness and ovarian cysts as measured by ultrasound in asymptomatic postmenopausal breast cancer patients on various adjuvant treatments including tamoxifen. Anticancer Res. 1997 Sep-Oct;17(5B):3821–3824. [PubMed] [Google Scholar]
  56. Magriples U., Naftolin F., Schwartz P. E., Carcangiu M. L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993 Mar;11(3):485–490. doi: 10.1200/JCO.1993.11.3.485. [DOI] [PubMed] [Google Scholar]
  57. Marshall E. Tamoxifen. 'A big deal,' but a complex hand to play. Science. 1998 Apr 10;280(5361):196–196. doi: 10.1126/science.280.5361.196b. [DOI] [PubMed] [Google Scholar]
  58. McGonigle K. F., Lantry S. A., Odom-Maryon T. L., Chai A., Vasilev S. A., Simpson J. F. Histopathologic effects of tamoxifen on the uterine epithelium of breast cancer patients: analysis by menopausal status. Cancer Lett. 1996 Mar 19;101(1):59–66. doi: 10.1016/0304-3835(96)04114-6. [DOI] [PubMed] [Google Scholar]
  59. McGonigle K. F., Shaw S. L., Vasilev S. A., Odom-Maryon T., Roy S., Simpson J. F. Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy. Am J Obstet Gynecol. 1998 Jun;178(6):1145–1150. doi: 10.1016/s0002-9378(98)70315-1. [DOI] [PubMed] [Google Scholar]
  60. Neven P., De Muylder X., Van Belle Y., Van Hooff I., Vanderick G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet. 1998 Jan 3;351(9095):36–36. doi: 10.1016/s0140-6736(05)78091-0. [DOI] [PubMed] [Google Scholar]
  61. Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol. 1990 May-Jun;35(2-3):235–238. doi: 10.1016/0028-2243(90)90167-y. [DOI] [PubMed] [Google Scholar]
  62. Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E. Tamoxifen and the uterus and endometrium. Lancet. 1989 Feb 18;1(8634):375–375. [PubMed] [Google Scholar]
  63. Newbold R. R., Jefferson W. N., Padilla-Burgos E., Bullock B. C. Uterine carcinoma in mice treated neonatally with tamoxifen. Carcinogenesis. 1997 Dec;18(12):2293–2298. doi: 10.1093/carcin/18.12.2293. [DOI] [PubMed] [Google Scholar]
  64. Noguchi S., Motomura K., Inaji H., Imaoka S., Koyama H. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer. 1993 Jul 1;72(1):131–136. doi: 10.1002/1097-0142(19930701)72:1<131::aid-cncr2820720125>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  65. Nuovo M. A., Nuovo G. J., McCaffrey R. M., Levine R. U., Barron B., Winkler B. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol. 1989;8(2):125–131. doi: 10.1097/00004347-198906000-00005. [DOI] [PubMed] [Google Scholar]
  66. Oral contraception and genital-tract malignancy. Lancet. 1989 Feb 18;1(8634):376–377. [PubMed] [Google Scholar]
  67. PETERSON W. F., NOVAK E. R. Endometrial polyps. Obstet Gynecol. 1956 Jul;8(1):40–49. [PubMed] [Google Scholar]
  68. Perry R. R., Kang Y., Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol. 1995 May;2(3):238–245. doi: 10.1007/BF02307030. [DOI] [PubMed] [Google Scholar]
  69. Powles T., Eeles R., Ashley S., Easton D., Chang J., Dowsett M., Tidy A., Viggers J., Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998 Jul 11;352(9122):98–101. doi: 10.1016/S0140-6736(98)85012-5. [DOI] [PubMed] [Google Scholar]
  70. Rea D., Poole C., Gray R. Adjuvant tamoxifen: how long before we know how long? BMJ. 1998 May 16;316(7143):1518–1519. doi: 10.1136/bmj.316.7143.1518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Rutqvist L. E., Johansson H., Signomklao T., Johansson U., Fornander T., Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995 May 3;87(9):645–651. doi: 10.1093/jnci/87.9.645. [DOI] [PubMed] [Google Scholar]
  72. Sherman B. M., Chapler F. K., Crickard K., Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest. 1979 Aug;64(2):398–404. doi: 10.1172/JCI109475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Shushan A., Peretz T., Uziely B., Lewin A., Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):141–144. doi: 10.1016/s0002-9378(96)70386-1. [DOI] [PubMed] [Google Scholar]
  74. Silva E. G., Tornos C. S., Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994 Jul;13(3):248–258. doi: 10.1097/00004347-199407000-00009. [DOI] [PubMed] [Google Scholar]
  75. Song J., Standley P. R., Zhang F., Joshi D., Gappy S., Sowers J. R., Ram J. L. Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther. 1996 Jun;277(3):1444–1453. [PubMed] [Google Scholar]
  76. Touraine P., Driguez P., Cartier I., Yaneva H., Kuttenn F., Mauvais-Jarvis P. Lack of induction of endometrial hyperplasia with tamoxifen. Lancet. 1995 Jan 28;345(8944):254–255. [PubMed] [Google Scholar]
  77. Veronesi U., Maisonneuve P., Costa A., Sacchini V., Maltoni C., Robertson C., Rotmensz N., Boyle P. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet. 1998 Jul 11;352(9122):93–97. doi: 10.1016/s0140-6736(98)85011-3. [DOI] [PubMed] [Google Scholar]
  78. White I. N., de Matteis F., Davies A., Smith L. L., Crofton-Sleigh C., Venitt S., Hewer A., Phillips D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992 Dec;13(12):2197–2203. doi: 10.1093/carcin/13.12.2197. [DOI] [PubMed] [Google Scholar]
  79. Williams G. M., Iatropoulos M. J., Djordjevic M. V., Kaltenberg O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis. 1993 Feb;14(2):315–317. doi: 10.1093/carcin/14.2.315. [DOI] [PubMed] [Google Scholar]
  80. Yager J. D., Roebuck B. D., Paluszcyk T. L., Memoli V. A. Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats. Carcinogenesis. 1986 Dec;7(12):2007–2014. doi: 10.1093/carcin/7.12.2007. [DOI] [PubMed] [Google Scholar]
  81. Zhao Y., Hague S., Manek S., Zhang L., Bicknell R., Rees M. C. PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene. 1998 Jan 22;16(3):409–415. doi: 10.1038/sj.onc.1201768. [DOI] [PubMed] [Google Scholar]
  82. van Leeuwen F. E., Benraadt J., Coebergh J. W., Kiemeney L. A., Gimbrère C. H., Otter R., Schouten L. J., Damhuis R. A., Bontenbal M., Diepenhorst F. W. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994 Feb 19;343(8895):448–452. doi: 10.1016/s0140-6736(94)92692-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES